---
document_datetime: 2025-11-23 08:05:31
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/rivastigmine-3m-health-care-ltd.html
document_name: rivastigmine-3m-health-care-ltd.html
version: success
processing_time: 0.095636
conversion_datetime: 2025-12-28 12:12:17.071409
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Rivastigmine 3M Health Care Ltd

[RSS](/en/individual-human-medicine.xml/65545)

##### Withdrawn

This medicine's authorisation has been withdrawn

rivastigmine

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Rivastigmine 3M Health Care Ltd](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 19 August 2014, the European Commission withdrew the marketing authorisation for Rivastigmine 3M Health Care Ltd (rivastigmine, transdermal patches) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, 3M Health Care Ltd, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Rivastigmine 3M Health Care Ltd was granted marketing authorisation in the EU on 3 April 2014 for the treatment of mild to moderately severe Alzheimer's dementia.

Rivastigmine 3M Health Care Ltd is a generic medicine of Exelon. There are other generic medicinal products of Exelon authorised and marketed in the EU. Rivastigmine 3M Health Care Ltd. is an identical product to Rivastigmine Actavis (transdermal patches), which is authorised in the EU to treat patients with mild to moderately severe Alzheimer's dementia.

Rivastigmine 3M Health Care Ltd was a duplicate application to Rivastigmine Actavis Transdermal Patches.

The European Public Assessment Report (EPAR) for Rivastigmine 3M Health Care Ltd is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

Rivastigmine 3M Health Care Ltd : EPAR - Summary for the public

Reference Number: EMA/58565/2014

English (EN) (543.73 KB - PDF)

**First published:** 14/04/2014

**Last updated:** 18/09/2014

[View](/en/documents/overview/rivastigmine-3m-health-care-ltd-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-543)

български (BG) (1.13 MB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/bg/documents/overview/rivastigmine-3m-health-care-ltd-epar-summary-public_bg.pdf)

español (ES) (544.14 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/es/documents/overview/rivastigmine-3m-health-care-ltd-epar-summary-public_es.pdf)

čeština (CS) (674.04 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/cs/documents/overview/rivastigmine-3m-health-care-ltd-epar-summary-public_cs.pdf)

dansk (DA) (565.02 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/da/documents/overview/rivastigmine-3m-health-care-ltd-epar-summary-public_da.pdf)

Deutsch (DE) (546.81 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/de/documents/overview/rivastigmine-3m-health-care-ltd-epar-summary-public_de.pdf)

eesti keel (ET) (545.38 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/et/documents/overview/rivastigmine-3m-health-care-ltd-epar-summary-public_et.pdf)

ελληνικά (EL) (640.76 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/el/documents/overview/rivastigmine-3m-health-care-ltd-epar-summary-public_el.pdf)

français (FR) (567.87 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/fr/documents/overview/rivastigmine-3m-health-care-ltd-epar-summary-public_fr.pdf)

hrvatski (HR) (566.41 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/hr/documents/overview/rivastigmine-3m-health-care-ltd-epar-summary-public_hr.pdf)

italiano (IT) (542.74 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/it/documents/overview/rivastigmine-3m-health-care-ltd-epar-summary-public_it.pdf)

latviešu valoda (LV) (625.4 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/lv/documents/overview/rivastigmine-3m-health-care-ltd-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (568.62 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/lt/documents/overview/rivastigmine-3m-health-care-ltd-epar-summary-public_lt.pdf)

magyar (HU) (602.99 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/hu/documents/overview/rivastigmine-3m-health-care-ltd-epar-summary-public_hu.pdf)

Malti (MT) (609.46 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/mt/documents/overview/rivastigmine-3m-health-care-ltd-epar-summary-public_mt.pdf)

Nederlands (NL) (549.82 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/nl/documents/overview/rivastigmine-3m-health-care-ltd-epar-summary-public_nl.pdf)

polski (PL) (609.98 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/pl/documents/overview/rivastigmine-3m-health-care-ltd-epar-summary-public_pl.pdf)

português (PT) (544.77 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/pt/documents/overview/rivastigmine-3m-health-care-ltd-epar-summary-public_pt.pdf)

română (RO) (571.48 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/ro/documents/overview/rivastigmine-3m-health-care-ltd-epar-summary-public_ro.pdf)

slovenčina (SK) (609.61 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/sk/documents/overview/rivastigmine-3m-health-care-ltd-epar-summary-public_sk.pdf)

slovenščina (SL) (1.08 MB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/sl/documents/overview/rivastigmine-3m-health-care-ltd-epar-summary-public_sl.pdf)

Suomi (FI) (585.72 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/fi/documents/overview/rivastigmine-3m-health-care-ltd-epar-summary-public_fi.pdf)

svenska (SV) (542.13 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/sv/documents/overview/rivastigmine-3m-health-care-ltd-epar-summary-public_sv.pdf)

Rivastigmine 3M Health Care Ltd : EPAR - Risk-management-plan summary

English (EN) (554.05 KB - PDF)

**First published:** 14/04/2014

**Last updated:** 18/09/2014

[View](/en/documents/rmp-summary/rivastigmine-3m-health-care-ltd-epar-risk-management-plan-summary_en.pdf)

## Product information

Rivastigmine 3M Health Care Ltd : EPAR - Product Information

English (EN) (797.74 KB - PDF)

**First published:** 14/04/2014

**Last updated:** 18/09/2014

[View](/en/documents/product-information/rivastigmine-3m-health-care-ltd-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-798)

български (BG) (2.05 MB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/bg/documents/product-information/rivastigmine-3m-health-care-ltd-epar-product-information_bg.pdf)

español (ES) (846.28 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/es/documents/product-information/rivastigmine-3m-health-care-ltd-epar-product-information_es.pdf)

čeština (CS) (1.5 MB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/cs/documents/product-information/rivastigmine-3m-health-care-ltd-epar-product-information_cs.pdf)

dansk (DA) (804.55 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/da/documents/product-information/rivastigmine-3m-health-care-ltd-epar-product-information_da.pdf)

Deutsch (DE) (869.95 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/de/documents/product-information/rivastigmine-3m-health-care-ltd-epar-product-information_de.pdf)

eesti keel (ET) (829.46 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/et/documents/product-information/rivastigmine-3m-health-care-ltd-epar-product-information_et.pdf)

ελληνικά (EL) (2.46 MB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/el/documents/product-information/rivastigmine-3m-health-care-ltd-epar-product-information_el.pdf)

français (FR) (841.22 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/fr/documents/product-information/rivastigmine-3m-health-care-ltd-epar-product-information_fr.pdf)

hrvatski (HR) (911.22 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/hr/documents/product-information/rivastigmine-3m-health-care-ltd-epar-product-information_hr.pdf)

íslenska (IS) (836.88 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/is/documents/product-information/rivastigmine-3m-health-care-ltd-epar-product-information_is.pdf)

italiano (IT) (845.3 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/it/documents/product-information/rivastigmine-3m-health-care-ltd-epar-product-information_it.pdf)

latviešu valoda (LV) (1.66 MB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/lv/documents/product-information/rivastigmine-3m-health-care-ltd-epar-product-information_lv.pdf)

lietuvių kalba (LT) (973.26 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/lt/documents/product-information/rivastigmine-3m-health-care-ltd-epar-product-information_lt.pdf)

magyar (HU) (1.47 MB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/hu/documents/product-information/rivastigmine-3m-health-care-ltd-epar-product-information_hu.pdf)

Malti (MT) (1.62 MB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/mt/documents/product-information/rivastigmine-3m-health-care-ltd-epar-product-information_mt.pdf)

Nederlands (NL) (846.75 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/nl/documents/product-information/rivastigmine-3m-health-care-ltd-epar-product-information_nl.pdf)

norsk (NO) (799.82 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/no/documents/product-information/rivastigmine-3m-health-care-ltd-epar-product-information_no.pdf)

polski (PL) (1.62 MB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/pl/documents/product-information/rivastigmine-3m-health-care-ltd-epar-product-information_pl.pdf)

português (PT) (851.44 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/pt/documents/product-information/rivastigmine-3m-health-care-ltd-epar-product-information_pt.pdf)

română (RO) (1.01 MB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/ro/documents/product-information/rivastigmine-3m-health-care-ltd-epar-product-information_ro.pdf)

slovenčina (SK) (1.54 MB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/sk/documents/product-information/rivastigmine-3m-health-care-ltd-epar-product-information_sk.pdf)

slovenščina (SL) (1.44 MB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/sl/documents/product-information/rivastigmine-3m-health-care-ltd-epar-product-information_sl.pdf)

Suomi (FI) (857.33 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/fi/documents/product-information/rivastigmine-3m-health-care-ltd-epar-product-information_fi.pdf)

svenska (SV) (819.74 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/sv/documents/product-information/rivastigmine-3m-health-care-ltd-epar-product-information_sv.pdf)

19/08/2014

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Rivastigmine 3M Health Care Ltd : EPAR - All Authorised presentations

English (EN) (479.37 KB - PDF)

**First published:** 14/04/2014

**Last updated:** 18/09/2014

[View](/en/documents/all-authorised-presentations/rivastigmine-3m-health-care-ltd-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-636)

български (BG) (517.34 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/bg/documents/all-authorised-presentations/rivastigmine-3m-health-care-ltd-epar-all-authorised-presentations_bg.pdf)

español (ES) (461.14 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/es/documents/all-authorised-presentations/rivastigmine-3m-health-care-ltd-epar-all-authorised-presentations_es.pdf)

čeština (CS) (500.09 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/cs/documents/all-authorised-presentations/rivastigmine-3m-health-care-ltd-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (460.86 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/da/documents/all-authorised-presentations/rivastigmine-3m-health-care-ltd-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (460.9 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/de/documents/all-authorised-presentations/rivastigmine-3m-health-care-ltd-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (460.65 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/et/documents/all-authorised-presentations/rivastigmine-3m-health-care-ltd-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (500.64 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/el/documents/all-authorised-presentations/rivastigmine-3m-health-care-ltd-epar-all-authorised-presentations_el.pdf)

français (FR) (460.94 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/fr/documents/all-authorised-presentations/rivastigmine-3m-health-care-ltd-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (470.73 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/hr/documents/all-authorised-presentations/rivastigmine-3m-health-care-ltd-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (460.76 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/is/documents/all-authorised-presentations/rivastigmine-3m-health-care-ltd-epar-all-authorised-presentations_is.pdf)

italiano (IT) (460.77 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/it/documents/all-authorised-presentations/rivastigmine-3m-health-care-ltd-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (488.93 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/lv/documents/all-authorised-presentations/rivastigmine-3m-health-care-ltd-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (474.11 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/lt/documents/all-authorised-presentations/rivastigmine-3m-health-care-ltd-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (477.82 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/hu/documents/all-authorised-presentations/rivastigmine-3m-health-care-ltd-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (488.47 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/mt/documents/all-authorised-presentations/rivastigmine-3m-health-care-ltd-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (460.81 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/nl/documents/all-authorised-presentations/rivastigmine-3m-health-care-ltd-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (460.67 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/no/documents/all-authorised-presentations/rivastigmine-3m-health-care-ltd-epar-all-authorised-presentations_no.pdf)

polski (PL) (478.3 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/pl/documents/all-authorised-presentations/rivastigmine-3m-health-care-ltd-epar-all-authorised-presentations_pl.pdf)

português (PT) (460.82 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/pt/documents/all-authorised-presentations/rivastigmine-3m-health-care-ltd-epar-all-authorised-presentations_pt.pdf)

română (RO) (473.86 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/ro/documents/all-authorised-presentations/rivastigmine-3m-health-care-ltd-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (483.1 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/sk/documents/all-authorised-presentations/rivastigmine-3m-health-care-ltd-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (485.61 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/sl/documents/all-authorised-presentations/rivastigmine-3m-health-care-ltd-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (460.58 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/fi/documents/all-authorised-presentations/rivastigmine-3m-health-care-ltd-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (460.82 KB - PDF)

**First published:**

14/04/2014

**Last updated:**

18/09/2014

[View](/sv/documents/all-authorised-presentations/rivastigmine-3m-health-care-ltd-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Rivastigmine 3M Health Care Ltd Active substance rivastigmine International non-proprietary name (INN) or common name rivastigmine Therapeutic area (MeSH) Alzheimer Disease Anatomical therapeutic chemical (ATC) code N06DA03

### Pharmacotherapeutic group

- Psychoanaleptics
- Anticholinesterases

### Therapeutic indication

Symptomatic treatment of mild to moderately severe Alzheimer's dementia.

## Authorisation details

EMA product number EMEA/H/C/003824

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

3M Health Care Limited

1 Morley Street Loughborough Leicestershire LE11 1EP United Kingdom

Opinion adopted 23/01/2014 Marketing authorisation issued 03/04/2014 Withdrawal of marketing authorisation 19/08/2014 Revision 1

## Assessment history

## Initial marketing authorisation documents

Rivastigmine 3M Health Care Ltd : EPAR - Public assessment report

Adopted

Reference Number: EMA/111203/2014

English (EN) (825.2 KB - PDF)

**First published:** 14/04/2014

**Last updated:** 18/09/2014

[View](/en/documents/assessment-report/rivastigmine-3m-health-care-ltd-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Rivastigmine 3M Health Care Ltd

Adopted

Reference Number: EMA/CHMP/25190/2014

English (EN) (543.63 KB - PDF)

**First published:** 24/01/2014

**Last updated:** 18/09/2014

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-rivastigmine-3m-health-care-ltd_en.pdf)

#### News on Rivastigmine 3M Health Care Ltd

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 January 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-january-2014) 24/01/2014

**This page was last updated on** 18/09/2014

## Share this page

[Back to top](#main-content)